Anthrax immune globulin Injection
- Brand(s)
- Anthrasil
- Category(s)
- other
- SPL Type(s)
- Plasma Derivative
- Master SPL
- Cangene Corporation (2015-11-12)
- Oldest Current Product
- 2015-10-05
- License(s)
- BLA
- RxNORM
- INJECTION\ANTHRAX IMMUNE GLOBULIN
- SPL Active
- INTRAVENOUS\LIQUID\ANTHRAX IMMUNE GLOBULIN HUMAN
- SPL Moiety
- INTRAVENOUS\LIQUID\ANTHRAX IMMUNE GLOBULIN HUMAN
product(s) by strength(s)
anthrax immune globulin, human 60 unt injection
| # | id | brand | category | labeler | first marketed | active ingredient(s) | route | dose form | application | spl |
|---|
| 1 | 604920249 | Anthrasil | BLA | Cangene Corporation | 2015-10-05 | ANTHRAX IMMUNE GLOBULIN HUMAN | INTRAVENOUS | LIQUID | 125562 | 97cc9a89-6fe0-424e-82d1-0cf9d19444db |
| # | id | title | approved | tradenames | fda division |
|---|
| 1 | 125562 | Anthrax Immune GlobulinIntravenous (Human) Application | 2015-03-24 | Anthrasil | CBER |
| # | id | title | category | type | labeler | labeler act | last update | version | product(s) |
|---|
| 1 | 97cc9a89-6fe0-424e-82d1-0cf9d19444db (view SPL) | These highlights do not include all the information needed to use ANTHRASIL safely and effectively. See full prescribing information for ANTHRASIL.ANTHRASIL [Anthrax Immune Globulin Intravenous (Human)], sterile solution for infusionInitial U.S. Approval: 2015 | other | Plasma Derivative | Cangene Corporation | MANUFACTURE | 2015-11-12 | 1 | 604920249 |